Introduction

This annual report on Form 10-KSB contains certain forward-looking " Safe Harbor" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E the Securities Act of 1934 and Item 16 related Risk Factors incorporated herein. Actual events or results may differ materially from those projected in the forward-looking statements as a result of the factors described herein. Such forward-looking statements include, but are not limited to, statements concerning business strategy, development and introduction of new products, research and development, marketing, sales and distribution, manufacturing, competition, third-party reimbursement, government regulation (including, but not limited to, FDA requirements), continued clinical trial relationships and operating and capital requirements. Mediscience is in full compliance with SEC regulation FD "Full Disclosure" requirements, adopted August 10, 2000 (see SEC release No. 33-7881), by exclusive reporting of material events (disclosures where it is reasonably foreseeable that the information will result in trading in an issuer's securities), through periodic 8-K filings and complementary postings on its internet site MEDISCIENCETECH.com e.g Sarbanes Compliance.

Safe Harbor Information of importance to our shareholders: Effective October, 2003 SEC III: Rule 10b-18 Safe Harbor Changes are statutorily applicable to the repurchase of a company's common stock in the open market. SEC Rule 10b-18 change is not presently applicable to registrant. The Company has no present or future commitment or intentions to re-purchase any of its outstanding common stock.